» Articles » PMID: 31706896

[Breast Cancer Epidemiology]

Overview
Journal Presse Med
Specialty General Surgery
Date 2019 Nov 11
PMID 31706896
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

The breast is the leading cancer site in women throughout the world. That said, breast cancer incidence varies widely, ranging from 27/100,000 (Central-East Asia and Africa) to 85-94/100,000 (Australia, North America and Western Europe). Its frequency in France is among the highest in Europe. While in most countries, its incidence has been increasing for more than 40 years, in a few other countries (USA, Canada, Australia, France…), it has been decreasing since 2000-2005. Possibly due to a substantial reduction of hormone-based treatments at menopause, the decrease may be transient. It is also the leading cause of female cancer deaths in almost all countries, with the exception of the most economically developed, in which it is currently second to lung cancer. That much said, for thirty years in highly industrialized countries such as France, breast cancer mortality has been declining. Taken together, early diagnosis and improved treatment explain this success. In France, 5-year survival and 10-year survival approximate 88 % and 78 % respectively; these rates are among the most elevated in Western Europe. Excess mortality due to breast cancer is consequently low (<5 %) but variable according to age, and maximal during the first two years of follow-up. Several thousand epidemiological studies on risk factors for breast cancer have been carried out worldwide; it is difficult to draw up an overall assessment, especially insofar as the identified factors interact and vary according to whether the cancers occur before or after menopause and depending on their histological, biological (receptors) or molecular characteristics. Moreover, their prevalence varies in time and from one region to another. For the majority of these factors, the level of relative risk is≤2. Genetic particularities: presence of proliferative mastopathy, a first child after 35 years of age and thoracic irradiation are the sole factors entailing relative risk from 2 to 5 (comparatively speaking, the risk levels associated with tobacco consumption reach values from 10 to 20, and in some cases even higher). However, exposure to risk factors≤2 may be relatively frequent and consequently favorable to development of a substantial number of breast cancers. Estimation (based on degree of risk and frequency of exposure) of the proportion of risk attributable to a given factor facilitates decision-making aimed at determining the most effective primary prevention actions. Taking into consideration the identified factors pertaining to post-menopausal cancers, only 35 % [23 to 45 %] of the attributable proportions could be reduced by primary prevention. In view of achieving this level of reduction, it is possible to put forward the following recommendations: for the women themselves: have a first child before the age of 30, breastfeed for several months, engage in sufficiently intense and regular physical activity, avoid or reduce excess weight after turning thirty, avoid exposure to active or passive smoking, limit alcohol consumption; for their physicians: do not prescribe pointless thoracic irradiations (unnecessary mammography in particular) or unjustified hormonal treatments. *persons/years.

Citing Articles

Synergistic therapeutic effects of pertuzumab and pyrrolitinib in HER-2-positive breast cancer: modulation of the PI3K/AKT pathway.

Zhu X, Xu Y, Zheng X, Li Y Am J Cancer Res. 2025; 15(1):141-152.

PMID: 39949924 PMC: 11815364. DOI: 10.62347/COSC7070.


Effects of an Easily Implemented Physical Exercise Program on the Ventricular Ejection Fraction of Women with Breast Cancer Undergoing Chemotherapy.

Moreira T, Pimenta N, Teixeira A, Pinheiro B, Canario-Lemos R, Peixoto R Int J Environ Res Public Health. 2025; 22(1).

PMID: 39857548 PMC: 11765345. DOI: 10.3390/ijerph22010094.


Clinical utility of quantitative ultrasonography parameters combined with serum cancer antigen 15‑3, human epidermal growth factor receptor 2 and soluble E‑cadherin in diagnosing mass‑type breast cancer.

Hu K, Wang Y, Ma Y, Xiu C Oncol Lett. 2025; 29(3):133.

PMID: 39822943 PMC: 11737295. DOI: 10.3892/ol.2025.14879.


Functional Analysis and Experimental Validation of the Prognostic and Immune Effects of the Oncogenic Protein CDC45 in Breast Cancer.

Zhang J, Li L, Cao M, Liu X, Yi Z, Liu S Breast Cancer (Dove Med Press). 2025; 17():11-25.

PMID: 39811603 PMC: 11727330. DOI: 10.2147/BCTT.S497975.


Regulation of the β‑catenin/LEF‑1 pathway by the siRNA knockdown of RUVBL1 expression inhibits breast cancer cell proliferation, migration and invasion.

Zhang X, Cui D, Sun W, Yang G, Wang W, Mi C Oncol Rep. 2024; 53(2).

PMID: 39670302 PMC: 11667213. DOI: 10.3892/or.2024.8855.